Marinomed

What Marinomed does

Marinomed Biotech AG is an Austrian biopharmaceutical company headquartered in Korneuburg, Lower Austria, founded in 2006 as a spin-off from the University of Veterinary Medicine Vienna and listed on the Vienna Stock Exchange (MARI) since February 2019. The company operates two proprietary technology platforms: Marinosolv®, a solubilization technology that generates aqueous formulations from poorly water-soluble compounds to dramatically improve bioavailability and enable lower-dose therapeutics; and Carragelose® (iota-carrageenan), a virus-blocking compound derived from red seaweed with demonstrated activity against SARS-CoV-2 variants, influenza A, and respiratory syncytial virus (RSV). Its clinical-stage prescription pipeline includes Budesolv (aqueous budesonide nasal spray for severe allergic rhinitis, Phase III complete), Tacrosolv (topical ophthalmic tacrolimus for inflammatory eye diseases, Phase II complete), and Satiasolv (water-based CBD formulation), alongside the Solv4U technology-partnership offering that licenses Marinosolv formulation services to external pharmaceutical partners.

Name

Marinomed

Legal name

Marinomed Biotech AG

Website

https://marinomed.com

Company type

Public

Founded year

2006

Operating status

Operating

Headcount range

11–50 employees

Short description

Marinomed Biotech AG is an Austrian biopharmaceutical company that develops prescription and OTC products for viral infectious diseases and immunological disorders using its proprietary Marinosolv® solubilization and Carragelose® antiviral platforms, licensing commercialized products to global pharmaceutical partners.

Ownership category

akta.pro rank

Product category

Biopharmaceuticals

NAICS

Pharmaceutical Preparation Manufacturing (325412), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Immunology & Inflammation Pharmaceuticals (HLAIAAAD)

akta.pro secondary industries

Bioprocess Development & Scale-Up/Scale-Down Platforms (DoE, high-throughput, modeling) (HLAAAJAF), Infectious Disease & Antimicrobials Pharmaceuticals (HLAIAAAG)

Keywords

• Biopharmaceutical development
• Virus-blocking therapeutics
• Drug solubilization platform
• Antiviral nasal sprays
• Immunology treatments

Headquarters

HQ city

Vienna

HQ country

Austria

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain

Revenue model

1. OTC Product Licensing & Royalties: OTC medical devices (nasal sprays, eye drops) developed up to market approval, then manufactured by CMOs and outlicensed to pharmaceutical partners for global marketing and distribution. Revenue comes from licensing fees, milestone payments, and ongoing royalties from product sales across 40+ countries.
2. Rx Pharmaceutical Licensing: Prescription pharmaceutical products based on Marinosolv technology are partnered during or after Phase II trials. Partnerships include upfront payments, development milestones, and royalty payments, while commercialization (manufacturing and distribution) remains with the licensee.
3. Solv4U Technology Partnerships: Marinosolv technology is made available to external customers through Solv4U technology collaborations and formulation development services. First long-term partnership established with Shanghai-based SPH Sine Pharmaceutical Laboratories Co. Ltd. Includes fee-for-service development and future milestone payments.
4. Strategic Partnerships - Marinosolv Platform: Worldwide exclusive licensing arrangements for specific applications of the Marinosolv technology platform, such as the 2026 partnership with Phargentis SA for inhalation therapy. Includes fee-for-service development, long-term milestone payments, and future royalties on product sales.

Go-to-market motion1 record

Distribution channels4 records

Marketing channels5 records

Core offering

Marinomed Biotech AG develops biopharmaceutical products based on two proprietary technology platforms: the Marinosolv solubilization technology, which dramatically improves solubility and bioavailability of poorly water-soluble compounds, and Carragelose, a virus-blocking compound derived from red seaweed. The company develops prescription (Rx) products for immunological disorders (Budesolv, Tacrosolv, Satiasolv) and OTC products (nasal sprays, lozenges) for viral respiratory infections, then outlicenses these to pharmaceutical partners for manufacturing and global commercialization.

Product overview

Marinomed Biotech AG is a biopharmaceutical company with two core technology platforms and multiple product portfolios. The company develops pharmaceutical products and medical devices in virology and immunology using its proprietary Marinosolv solubilization technology and Carragelose (iota-carrageenan) compound. The product portfolio includes prescription products in clinical development (Budesolv for allergic rhinitis, Tacrosolv for inflammatory eye diseases, Satiasolv for CBD-based therapies), a marketed OTC portfolio of Carragelose-based nasal sprays and lozenges for viral infections, and Solv4U technology partnership services offering Marinosolv access to external pharmaceutical partners.

Differentiator

Problem solved

Functional benefit

Brands

• Carragelose: Virus-blocking compound derived from red seaweed, marketed as nasal sprays and lozenges for treatment and prevention of viral respiratory infections including common cold and COVID-19.
• Budesolv
• Tacrosolv
• Satiasolv
• Solv4U

Products and services

• Budesolv An innovative aqueous budesonide nasal spray for treating severe allergic rhinitis, enabled by Marinosolv technology for improved solubility and bioavailability, with strong symptom relief at low doses and a preservative-free sterile formulation suitable for pediatric use.
• Tacrosolv A topically administered ophthalmic formulation containing tacrolimus for treating inflammatory diseases of the anterior segment of the eye, such as dry eye disease and atopic allergic keratoconjunctivitis, utilizing Marinosolv technology for enhanced tissue penetration and bioavailability.
• Satiasolv A water-based formulation containing Cannabidiol (CBD) derived from Cannabis sativa for nasal and oral use, enabled by Marinosolv technology to overcome CBD's poor solubility and lipophilic properties (BCS Class II), with preclinical data showing superior brain uptake compared to oil-based reference products.
• Carragelose (OTC portfolio) A virus-blocking compound derived from red seaweed (iota-carrageenan) used in OTC nasal sprays, lozenges, and eye drops for treating and preventing viral respiratory infections including common cold, influenza, SARS-CoV-2, and RSV. Marketed globally through licensing partnerships across 40+ countries.
• Marinosolv Technology Platform A proprietary solubilization technology platform that dramatically improves solubility and bioavailability of poorly water-soluble compounds, enabling faster therapeutic onset at lower doses. Used in Marinomed's own pipeline products and available to external partners through Solv4U technology collaborations for fee-for-service formulation development.
• Solv4U Technology Partnerships & Services Technology partnerships and formulation development services offering external pharmaceutical partners access to the Marinosolv solubilization technology for creating novel aqueous formulations of lipophilic compounds, including fee-for-service development and milestone/royalty arrangements.

Quantifiable outcome

• Carragelose demonstrated synergistic antiviral activity against SARS-CoV-2, Influenza A virus, and Respiratory Syncytial Virus when combined with elderberry extract
• +2 more outcomes

Named customers5 records

Segments3 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Seven partnerships are on record, tiered major, core and minor.

• Phargentis SAmajorStrategic or Co-development Partner · 19 May 2026Strategic partnership and worldwide exclusive license for Marinosolv® technology platform for inhalation formulation. Includes fee-for-service development, long-term milestone payments, and future royalties on product sales. Leverages Marinomed's expertise to enhance solubility and bioavailability of a specialized respiratory therapeutic.
• SPH Sine Pharmaceutical Laboratories Co. Ltd.majorStrategic or Co-development Partner · 1 January 2023First long-term Solv4U technology partnership with Shanghai-based company established in 2023. SPH Sine is a significant Chinese pharmaceutical development company.
• Procter & GamblecoreChannel Partner/ Reseller/ Distributor · 1 January 2022One of the most important license agreements for Carragelose®, covering the U.S. market. Procter & Gamble handles commercialization of Carragelose nasal spray products in the United States.
• Boehringer IngelheimcoreChannel Partner/ Reseller/ Distributor · 1 January 2010Licensing partnership established in 2010, initially covering 54 countries for Carragelose® products. Boehringer Ingelheim handles commercialization in licensed territories.
• Luoxin PharmaceuticalcoreChannel Partner/ Reseller/ DistributorPartnership for prescription (Rx) pharmaceutical products marked an important first step in Rx segment licensing. Luoxin Pharmaceutical handles commercialization in licensed territories.
• Iprona Lana SpAminorStrategic or Co-development PartnerCollaboration partner in research study published in 2026 demonstrating synergistic antiviral activity of European black elderberry fruit extract and iota-carrageenan against SARS-CoV-2, influenza A virus, and RSV.
• Friedrich-Alexander University Erlangen-NürnbergminorStrategic or Co-development PartnerAcademic research partner in collaboration with Iprona Lana SpA and Marinomed Biotech AG for study on synergistic antiviral activities published in Nutrients journal.

Scale indicators5 records

Recent moves9 records

Expansion highlights5 records

Direct peers

• BioGaia AB: Swedish small-cap biotech that commercializes proprietary probiotic strains via licensing and distribution partners across 100+ countries. Comparable in size, asset-light outlicensing model, and OTC consumer health orientation.
• MediGene AG: German small-cap biopharma focused on immuno-oncology and immunology. Comparable as a similarly-sized European innovator with clinical-stage assets and outlicensing as part of its commercial strategy.
• Pharming Group N.V. Dutch small-cap biopharma commercializing rare-disease therapies through specialty distribution. Comparable in size, European listing, and immunology/rare-disease focus, though with more direct commercialization.
• Molecular Partners AG: Swiss clinical-stage biotech with a proprietary platform (DARPin) generating multiple partnered programs. Comparable as a small European platform-biopharma reliant on partnerships for late-stage development and commercialization.
• GW Pharmaceuticals (Jazz Pharmaceuticals): Developed cannabinoid-based therapeutics (Sativex, Epidiolex) using proprietary formulation technology. Comparable to Marinomed's Satiasolv CBD program and to the broader theme of enabling poorly-soluble molecules through novel delivery.
• SCYNEXIS, Inc. US small-cap biopharma commercializing anti-infectives (ibrexafungerp) with partner-led distribution. Comparable in size, infectious-disease focus, and reliance on partnerships for commercialization.

Broad incumbents

• Evotec SE: Larger German drug discovery and development platform offering fee-for-service and co-development partnerships. Comparable as a technology-platform biotech with licensing-based revenue models, though far larger and broader in scope.
• AbCellera Biologics Inc. Canadian antibody discovery platform partnering with pharma on biologics. Comparable technology-licensing model and emphasis on partnerships, though larger and more focused on therapeutic antibodies.
• Novavax, Inc. US vaccine company targeting respiratory viruses (SARS-CoV-2, influenza, RSV). Comparable virology/respiratory focus, though much larger and reliant on direct commercialization rather than outlicensing.
• Vir Biotechnology, Inc. US clinical-stage biotech developing antivirals and immunotherapies against respiratory viruses. Comparable virology focus and partnered business model, though larger and more advanced.

Market position

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

• Xtwitter.com/Marinomed_AG
• LinkedInlinkedin.com/company/marinomed-biotech-ag

Revenue estimate

Valuation estimate

Number of profiles

Profiles13 records

Funding overview

Funding rounds7 records

Investors4 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Marinomed